What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs

PLoS Neglected Tropical Diseases

Volumn 9, Issue 10, 2015, Pages

  Kastner, Randee J ^a,b   Stone, Christopher M ^a,b   Steinmann, Peter ^a,b   Tanner, Marcel ^a,b   Tediosi, Fabrizio ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE ASSESSMENT; DISEASE CARRIER; DISEASE ERADICATION; DISEASE TRANSMISSION; HEALTH PROGRAM; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; LOIASIS; LYMPHATIC FILARIASIS; MASS DRUG ADMINISTRATION PROGRAM; MEDICAL GEOGRAPHY; RISK ASSESSMENT; SCALE UP; SPECIES ENDEMICITY; ELEPHANTIASIS, FILARIAL; HEALTH; PREVENTION AND CONTROL; STATISTICAL MODEL;

ANTIFILARIAL AGENT;

DISEASE ERADICATION; DISEASE TRANSMISSION, INFECTIOUS; ELEPHANTIASIS, FILARIAL; FILARICIDES; GLOBAL HEALTH; HUMANS; MODELS, STATISTICAL;

EID: 84945202432     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004147     Document Type: Article

References (41)

1. WHOGlobal programme to eliminate lymphatic filariasis: progress report for 2012. Wkly Epidemiol Rec. 2013;88(37): 389–99. Epub 2013/10/01. 24073461
2. de Souza DK, Koudou B, Kelly-Hope LA, Wilson MD, Bockarie MJ, Boakye DA, Diversity and transmission competence in lymphatic filariasis vectors in West Africa, and the implications for accelerated elimination of Anopheles-transmitted filariasis. Parasit Vectors. 2012;5: 259. doi: 10.1186/1756-3305-5-25923151383
3. Addiss DG, Dimock KA, Eberhard ML, Lammie PJ, Clinical, parasitologic, and immunologic observations of patients with hydrocele and elephantiasis in an area with endemic lymphatic filariasis. J Infect Dis. 1995;171(3): 755–8. 7876636
4. Suma TK, Shenoy RK, Kumaraswami V, A qualitative study of the perceptions, practices and socio-psychological suffering related to chronic brugian filariasis in Kerala, southern India. Ann Trop Med Parasitol. 2003;97(8): 839–45. 14754496
5. Perera M, Whitehead M, Molyneux D, Weerasooriya M, Gunatilleke G, Neglected patients with a neglected disease? A qualitative study of lymphatic filariasis. PLoS Negl Trop Dis. 2007;1(2): e128. 18060080
6. Weiss MG, Stigma and the social burden of neglected tropical diseases. PLoS Negl Trop Dis. 2008;2(5): e237. doi: 10.1371/journal.pntd.000023718478049
7. Centers for Disease Control and Prevention. Parasites—Lymphatic Filariasis27 April 2015. Available: http://www.cdc.gov/parasites/lymphaticfilariasis/gen_info/faqs.html.
8. Fact Sheet: Lymphatic Filariasis [Internet]. Geneva, Switzerland: World Health Organization; 2012. Available: http://www.who.int/mediacentre/factsheets/fs102/en/.
9. Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep. 1993;42(RR–16): 1–38. 8145708
10. Ottesen EA, Duke BO, Karam M, Behbehani K, Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ. 1997;75(6): 491–503. 9509621
11. Sugiyama H, Yamaguchi A, Murakami H, Japanese Corporate Initiatives in Global Health: Case Studies and Policy Recommendations. Tokyo, Japan: 2012.
12. Liverpool School of Tropical Medicine. Annual Report. Liverpool, U.K.: LSTM, 2007–2008.
13. Preventive Chemotherapy Databank Lymphatic Filariasis [Internet]. WHO. 2015 [cited 2015 January 20]. Available: http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/.
14. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350(9070): 18–22. 9217715
15. Alexander ND, Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination. Trans R Soc Trop Med Hyg. 2015. Epub 2015/01/13.
16. Molyneux DH, Hopkins DR, Zagaria N, Disease eradication, elimination and control: the need for accurate and consistent usage. Trends Parasitol. 2004;20(8): 347–51. 15246314
17. Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, et al. Global programme to eliminate lymphatic filariasis: the processes underlying programme success. PLoS Negl Trop Dis. 2014;8(12): e3328. doi: 10.1371/journal.pntd.000332825502758
18. Tediosi F, Steinmann P, de Savigny D, Tanner M, Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges. PLoS Negl Trop Dis. 2013;7(11): e2446. doi: 10.1371/journal.pntd.000244624244762
19. Walker DG, Lupp J. Guide for preparing an eradication investment case. 2011.
20. Provisional strategy for interrupting lymphatic filariasis transmission in loiasis-endemic countries: report on the meeting on lymphatic filariasis, malaria and integrated vector management. Accra, Ghana: WHO, 5–9 March 2012.
21. World Health OrganizationTraining in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis. Learner's guide. Geneva, Switzerland: WHO, 2013.
22. Passing H, Bablok A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem. 1983;21(11): 709–20. 6655447
23. Stolk WA, de Vlas SJ, Borsboom GJ, Habbema JD, LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages. Parasitology. 2008;135(13): 1583–98. doi: 10.1017/S003118200800043719006602
24. Stolk WA, ten Bosch QA, de Vlas SJ, Fischer PU, Weil GJ, Goldman AS, Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis. PLoS Negl Trop Dis. 2013;7(1): e1984. doi: 10.1371/journal.pntd.000198423301115
25. Michael E, Malecela-Lazaro MN, Maegga BT, Fischer P, Kazura JW, Mathematical models and lymphatic filariasis control: monitoring and evaluating interventions. Trends Parasitol. 2006;22(11): 529–35. 16971182
26. Pichon G, Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles-transmitted filariasis. Ann Trop Med Parasitol. 2002;96Suppl 2: S143–52. 12625927
27. Stolk WA, de Vlas SJ, Habbema JD, Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling. Filaria J. 2006;5: 5. 16569234
28. Norman RA, Chan MS, Srividya A, Pani SP, Ramaiah KD, Vanamail P, et al. EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis. Epidemiol Infect. 2000;124(3): 529–41. 10982078
29. Gambhir M, Bockarie M, Tisch D, Kazura J, Remais J, Spear R, et al. Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. BMC Biol. 2010;8: 22. doi: 10.1186/1741-7007-8-2220236528
30. Gambhir M, Michael E, Complex ecological dynamics and eradicability of the vector borne macroparasitic disease, lymphatic filariasis. PLoS One. 2008;3(8): e2874. doi: 10.1371/journal.pone.000287418716676
31. Michael E, Bundy DA, Grenfell BT, Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology. 1996;112 (Pt 4): 409–28. 8935952
32. United Nations, Department of Economic and Social Affairs, Population Division (2013). World Population Prospects: The 2012 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.227.
33. WHO, Rotary International, CDC. Global Polio Eradication Initiative (GPEI) Status Report. 29 April 2013.
34. Gillespie SH, Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother. 2002;46(2): 267–74. 11796329
35. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859): 2197–223. doi: 10.1016/S0140-6736(12)61689-423245608
36. Babu BV, Babu GR, Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Trans R Soc Trop Med Hyg. 2014;108(9): 538–49. doi: 10.1093/trstmh/tru05724728444
37. Reimer LJ, Thomsen EK, Tisch DJ, Henry-Halldin CN, Zimmerman PA, Baea ME, et al. Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med. 2013;369(8): 745–53. doi: 10.1056/NEJMoa120759423964936
38. Stone CM, Lindsay SW, Chitnis N, How effective is integrated vector management against malaria and lymphatic filariasis where the diseases are transmitted by the same vector?PLoS Negl Trop Dis. 2014;8(12): e3393. doi: 10.1371/journal.pntd.000339325501002
39. Noor AM, Mutheu JJ, Tatem AJ, Hay SI, Snow RW, Insecticide-treated net coverage in Africa: mapping progress in 2000–07. Lancet. 2009;373(9657): 58–67. doi: 10.1016/S0140-6736(08)61596-219019422
40. Giardina F, Kasasa S, Sie A, Utzinger J, Tanner M, Vounatsou P, Effects of vector-control interventions on changes in risk of malaria parasitaemia in sub-Saharan Africa: a spatial and temporal analysis. Lancet Glob Health. 2014;2(10): e601–15. doi: 10.1016/S2214-109X(14)70300-625304636
41. Stolk WA, Stone C, de Vlas SJ, Modelling lymphatic filariasis transmission and control: modelling frameworks, lessons learned and future directions. Adv Parasitol. 2015;87: 249–91. doi: 10.1016/bs.apar.2014.12.00525765197